• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·STAR.NS
Share

Strides Pharma Science Limited Stocks

₹ 1014.8Last Updated 23.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

₹ 1.01B

₹ 1014.8
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, India, and various other international markets. The company's operations are structured into two distinct segments: Pharmaceutical and Biopharmaceutical. It provides a diverse range of generic pharmaceuticals, available in multiple formats including tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Furthermore, Strides Pharma Science creates branded generic offerings for treating chronic ailments such as women's health issues, central nervous system disorders, cardiovascular conditions, diabetes, dermatological concerns, and probiotic support, marketed under brands like Renerve, Unibrol, Combiart, Duotab, and Vitafer. For institutional business, the company supplies drugs targeting infectious diseases, including anti-retrovirals, anti-malarials, anti-tuberculosis, and Hepatitis treatments. Incorporated in 1990, the company is headquartered in Bengaluru, India. It was formerly known as Strides Shasun Limited before adopting its current name in July 2018.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of STAR.NS is 1213 and suggests 19.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.10.2026 22:01

Solidigm Won't Go Public; New OpenAI Valuation: Key Points on the IPO by October 25

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds ramp up bets against euro to highest level since 2020

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026